Faruqi & Faruqi, LLP Launches An Investigation Against Progenics Pharmaceuticals, Inc. (PGNX) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading
national securities firm headquartered in New York City, is
investigating the Board of Directors of Progenics Pharmaceuticals, Inc.
(“Progenics” or the “Company”) (NasdaqGS: PGNX) for potential breaches
of fiduciary duties in connection with their conduct in seeking
shareholders’ approval for an increase in the number of available shares
under the Company’s 2005 Stock Incentive Plan.
Specifically, in the Proxy Statement filed by the Company with the
Securities and Exchange Commission on May 3, 2013, the Board of
Directors recommends that Progenics’ shareholders vote to approve an
increase in the number of available shares under the Company’s 2005
Stock Incentive Plan from 8,450,000 to 10,450,000. The issuance of the
additional shares could have a substantial dilutive effect on the shares
of Progenics common stock.
Request more information now by clicking here: www.faruqilaw.com/PGNX.
There is no cost or obligation to you.
Faruqi & Faruqi, LLP is a national law firm which represents investors
and individuals in class action litigation. The firm is focused on
providing exemplary legal services in complex litigation in the areas of
securities, shareholder, antitrust and consumer litigation, throughout
all phases of litigation. The firm has an experienced trial team which
has achieved significant victories on behalf of the firm’s clients.
If you own common stock in Progenics and wish to obtain additional
information and protect your investments free of charge, please visit us
at www.faruqilaw.com/PGNX
or contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@faruqilaw.com
or by telephone at (877) 247-4292 or (212) 983-9330.
Attorney Advertising. (C) 2013 Faruqi & Faruqi, LLP. The law firm
responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).
Prior results do not guarantee or predict a similar outcome with respect
to any future matter. We are happy to discuss your particular case.
<div class="copyright">
Copyright Business Wire 2013
</div>